Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

3 + 16 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called selpercatinib. The overall goal of this study is to find out how effective the study drug is in combination with radioactive iodine (I-131) in treating people with thyroid cancer. The study drug will be given in combination with treatments you will receive as part of your regular cancer care (I-131 and thyrotropin alfa).

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT05668962

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
23-021515
Official Title:
Restoration of Radioiodine Uptake with Selpercatinib in RET Fusion-Positive Radioiodine-Refractory Thyroid Cancer: A Phase 2 Study Performed in Collaboration with the International Thyroid Oncology Group (ITOG)
Study Phase:
Phase II
Eligible Age Range:
12 - 40 Years
Gender:
All
Study Categories:

Visit Criteria

The study will enroll male and female patients between 12 and 40 years of age that have been diagnosed with RET fusion-positive radioiodine-refractory thyroid cancer.

As a participant in this research, you will:

  • Receive a study drug called selpercatinib in combination with therapy you would receive as part of your regular cancer care (I-131 and thyrotropin alfa (rhTSH))
  • Complete frequent clinic visits at CHOP
  • Complete medication diaries
  • Have blood tests performed as part of your regular cancer care
  • Have tissue collected if you have a biopsy as part of your regular cancer care
  • Have MRIs and X-rays if you are under the age of 18
  • Have periodic imaging performed as part of your regular cancer care to evaluate your response to treatment
  • Have periodic EKGs and echocardiograms as part of your regular cancer care
Leader
Theodore W. Laetsch

Theodore Laetsch, MD